Grace Therapeutics annual ebitda
2019
2020
2021
2022
2023
2024
2025
2026
Grace Therapeutics EBITDA Growth & History (GRCE)
Grace Therapeutics's calculated EBITDA was −$11.1M for fiscal 2026.
View full Grace Therapeutics company overviewGrace Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | −$11.1M | $5.6M | — |
| 2025 | 2025-03-31 | −$16.7M | −$3.8M | — |
| 2024 | 2024-03-31 | −$12.8M | $39.2M | — |
| 2023 | 2023-03-31 | −$52.0M | −$36.4M | — |
| 2022 | 2022-03-31 | −$15.6M | −$94,000 | — |
| 2021 | 2021-03-31 | −$15.5M | $6.6M | — |
| 2020 | 2020-03-31 | −$22.1M | $10.0M | — |
| 2019 | 2019-03-31 | −$32.1M | — | — |
Grace Therapeutics quarterly ebitda
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | −$15.9M | −$12.8M | — |
| Q4 2026 | 2026-03-31 | −$3.0M | $172,000 | — |
| Q3 2026 | 2025-12-31 | −$2.4M | $1.3M | — |
| Q2 2026 | 2025-09-30 | −$2.5M | $2.3M | — |
| Q1 2026 | 2025-06-30 | −$3.1M | $1.9M | — |
| Q4 2025 | 2025-03-31 | −$3.2M | $83,000 | — |
| Q3 2025 | 2024-12-31 | −$3.7M | −$660,000 | — |
| Q2 2025 | 2024-09-30 | −$4.8M | −$2.7M | — |
| Q1 2025 | 2024-06-30 | −$5.0M | −$515,000 | — |
| Q4 2024 | 2024-03-31 | −$3.3M | $34.8M | — |
| Q3 2024 | 2023-12-31 | −$3.0M | $1.2M | — |
| Q2 2024 | 2023-09-30 | −$2.1M | $3.1M | — |
| Q1 2024 | 2023-06-30 | −$4.4M | $116,000 | — |
| Q4 2023 | 2023-03-31 | −$38.1M | −$33.7M | — |
| Q3 2023 | 2022-12-31 | −$4.2M | $239,000 | — |
| Q2 2023 | 2022-09-30 | −$5.2M | −$1.6M | — |
| Q1 2023 | 2022-06-30 | −$4.6M | −$1.4M | — |
| Q4 2022 | 2022-03-31 | −$4.4M | −$2.1M | — |
| Q3 2022 | 2021-12-31 | −$4.5M | −$2.5M | — |
| Q2 2022 | 2021-09-30 | −$3.6M | $4.1M | — |
| Q1 2022 | 2021-06-30 | −$3.1M | $428,000 | — |
| Q4 2021 | 2021-03-31 | −$2.3M | $1.1M | — |
| Q3 2021 | 2020-12-31 | −$2.0M | $3.6M | — |
| Q2 2021 | 2020-09-30 | −$7.7M | −$2.0M | — |
| Q1 2021 | 2020-06-30 | −$3.6M | $3.9M | — |
| Q4 2020 | 2020-03-31 | −$3.4M | — | — |
| Q3 2020 | 2019-12-31 | −$5.6M | — | — |
| Q2 2020 | 2019-09-30 | −$5.7M | — | — |
| Q1 2020 | 2019-06-30 | −$7.4M | — | — |
Grace Therapeutics ebitda trends
Over the last five reported fiscal years, Grace Therapeutics's ebitda increased from −$15.5M to −$11.1M, a change of $4.4M. The latest reported quarter, Q1 2027, shows −$15.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Grace Therapeutics filings at SEC.gov ↗